Table 5.
Univariate analysis - clinical and dosimetric factors and late urinary toxicity
| Variable | N Total | Toxicity Grade >=1 | % | p | Toxicity Grade >=2 | % | p | |
|---|---|---|---|---|---|---|---|---|
| Prostate volume | <45 | 27 | 3 | 11.1 | 0.024 | 2 | 7.4 | |
| (cc) | >45 | 12 | 6 | 50.0 | 1 | 8.3 | ||
| Clinical Stage | < T1c | 22 | 8 | 36.4 | 0.086 | 2 | 9.1 | 0.570 |
| >T1c | 17 | 1 | 5.9 | 1 | 5.9 | |||
| Number of Needles | <11 | 12 | 5 | 41.6 | 0.038 | 1 | 8.3 | 0.122 |
| >11 | 27 | 4 | 14.8 | 2 | 7.4 | |||
| Prostate volume | <45 | 27 | 3 | 11.1 | 0.024 | 2 | 7.4 | 0.539 |
| (cc) | >45 | 12 | 6 | 50.0 | 1 | 8.3 | ||
| Urethral dose (% prescribed dose) | <130 | 27 | 1 | 3.7 | <0.001 | 0 | 0.0 | 0.008 |
| >130 | 12 | 8 | 66.7 | 3 | 25.0 |
Toxicity scale runs from 1-3. NAAD: neoadjuvant androgen deprivation; HTN: systemic arterial hypertension; CAD: coronary arterial disease; DM: diabetes mellitus; IPSS: International prostate symptom score; IR: intermediate risk for biochemical failure; HR: high risk for biochemical failure.